Lv6
2510 积分 2024-01-29 加入
Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization
17天前
已完结
Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy
17天前
已完结
A Radioligand Competition Binding Protocol for Assessing the Association and Dissociation Rates of Unlabeled Compounds
1个月前
已关闭
Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib
2个月前
已完结
Progressive metastatic infantile fibrosarcoma with multiple acquired mutations
5个月前
已关闭
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
5个月前
已关闭
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
5个月前
已完结
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
5个月前
已完结
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
5个月前
已关闭
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
5个月前
已完结
皖公网安备34019202002308
